Modeling of delayed type hypersensitivity (DTH) in the non-human primate (NHP)

Drug Discovery Today: Disease Models

Volumn 5, Issue 2, 2008, Pages 63-71

  Córdoba, Francisco ^a   Wieczorek, Grazyna ^a   Preussing, Ellen ^a   Bigaud, Marc ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ALLERGEN; ANTIALLERGIC AGENT; APC 0576; CORREOLIDE; CORREOLIDE DERIVATRIVE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; HALOFUGINONE; K 108; K 14; MONOCLONAL ANTIBODY; OKT 8; PALMITOYLCARNITINE; PROTEIN INHIBITOR; RAPAMYCIN; TRIFLUOPERAZINE; UNCLASSIFIED DRUG;

ANIMAL WELFARE; ANTIGEN ANTIBODY REACTION; ANTIGENICITY; CELL INFILTRATION; CELLULAR IMMUNITY; CONTACT ALLERGY; DELAYED HYPERSENSITIVITY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG RESEARCH; ERYTHEMA; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; LOADING DRUG DOSE; MACROPHAGE MIGRATION; NONHUMAN; PRIMATE; REPRODUCIBILITY; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; SKIN ALLERGY; SKIN BIOPSY; SKIN INDURATION; SKIN INFLAMMATION; SKIN SENSITIZATION; SKIN TEST;

EID: 59249098669     PISSN: 17406757     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmod.2008.05.002     Document Type: Review

References (40)

1. 't Hart B.A., et al. Evaluating the validity of animal models for research into therapies for immune-based disorders. Drug Discov. Today 9 (2004) 517-524
2. Black C.A. Delayed Type Hypersensitivity: Current Theories with an Historic Perspective. Dermatol. Online J. 5 (1999) 7
3. Vukmanovic-Stejic M., et al. Mantoux Test as a model for a secondary immune response in humans. Immunol. Lett 107 (2006) 93-101
4. Bleavins M.R., et al. Cynomolgus monkeys (Macaca fascicularis) in preclinical immune function safety testing: development of a delayed-type hypersensitivity procedure. Toxicology 95 (1995) 103-112
5. Rosenstreich D.L. Evaluation of delayed hypersensitivity: from PPD to poison ivy. Allergy Proc. 14 (1993) 395-400
6. Yuzawa K., et al. APC0576: a novel small molecule, immunosuppressive agent effective in primate models. Transplantation 75 (2003) 1463-1468
7. Bussiere, J.L. (2004) Immunotoxicity, immunogenicity and immunopharmacology of therapeutic proteins. 55th Annual Meeting of the American College of Veterinary Pathologists (ACVP) & 39th Annual Meeting of the American Society of Clinical Pathology (ASVCP)
8. Di Pierro F., et al. Use of type I and type IV hypersensitivity responses to define the immunopharmacological profile of drugs. J. Pharmacol. Toxicol. Methods 37 (1997) 91-96
9. Walker, H.K. et al., III (1990) Skin testing for tuberculosis. In Clinical Methods: The History, Physical, and Laboratory Examinations (Hurst J.H., ed), pp. 245-248
10. Shibaki A., et al. Induction of skewed Th1/Th2 T-cell differentiation via subcutaneous immunization with Freund's adjuvant. Exp. Dermatol. 11 (2002) 126-134
11. Bugelski P.J., et al. Effects of sensitization to dinitrochlorobenzene (DNCB) on clinical pathology parameters and mitogen-mediated blastogenesis in cynomolgus monkeys (Macaca fascicularis). Toxicol. Pathol. 18 4 Pt 2 (1990) 643-650
12. Corcoran K.D., et al. An attempt to predict anergy in tuberculosis suspect cynomolgus monkeys. Lab. Anim. Sci. 41 (1991) 57-62
13. Taube M., et al. Action of dexamethasone in the supression of delayed-type hypersensitivity in reconstituted SCID mice. Inflamm. Res. 49 (2000) 548-552
14. Stewart V.A., et al. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. Vaccine 24 (2006) 6493-6502
15. Schmitz J.E., et al. A nonhuman primate model for the selective elimination of CD8+ lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154 (1999) 1923-1932
16. Mestas J., et al. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004) 2731-2738
17. Haley P.J. Species differences in the structure and function of the immune system. Toxicology 188 (2003) 49-71
18. Turk I J.L. The histology of delayed hypersensitivity chapter 3. In: Turk J.L. (Ed). Research Monographs in Immunology Delayed Hypersensitivity (1980), Elsevier/North Holland Biomedical Press 45-64
19. Sapolsky, R.M. (2005) The influence of social hierarchy on primate health. Science 29 308, 648-652
20. Dhabhar F.S. Acute stress enhances while chronic stress suppresses skin immunity. The role of stress hormones and leukocyte trafficking. Ann. N.Y. Acad. Sci. 917 (2000) 876-893
21. Davis J.A., et al. Delayed cutaneous hypersensitivity response in tetanus toxoid sensitized Rhesus monkeys: Predictor of anergy and value in tuberculin skin testing. Lab. Anim. Sci. 38 (1988) 413-416
22. Kimber I., et al. Skin sensitization testing in potency and risk assessment. Toxicol. Sci. 59 (2001) 198-208
23. Cobb A., et al. The use of hairless (IAF/HA-HO) guinea pigs for the determination of delayed-type hypersensitivity to tuberculin. Int. Immunopharmacol. 1 (2001) 349-353
24. Prud'homme G.J., et al. Cyclosporine, tolerance, and autoimmunity. Clin. Immunol. Immunopathol. 66 (1993) 185-192
25. Thomson A.W., et al. Modification of delayed-type hypersensitivity reactions to ovalbumin in cyclosporin A-treated guinea-pigs. Immunology 48 (1983) 301-308
26. Sakamoto Y., et al. Suppressive effect of cyclosporin A on delayed-type hypersensitivity to syngeneic testicular cells. J. Antibiot. (Tokyo) 47 (1994) 708-714
27. Geba G.P., et al. Topical tacrolimus and cyclosporin A differentially inhibit early and late effector phases of cutaneous delayed-type and immunoglobulin E hypersensitivity. Immunology 104 (2001) 235-242
28. Zimecki M., et al. Differential patterns of cyclosporine QA-induced inhibition of humoral and cellular immune responses to sheep erythrocytes in mices. Pol. J. Pharmacol. 53 (2001) 495-500
29. Gongora L., et al. On the activity of trifluoperazine and palmitoylcarnitine in mice: delayed hypersensitivity models. Life Sci. 66 (2000) PL183-PL188
30. Mochizuki M., et al. Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest. Ophthalmol. Vis. Sci. 26 (1985) 226-232
31. Leiba M., et al. Halofuginone inhibits NF-kappaB and p38 MAPK in activated T cells. J. Leukoc. Biol. 80 (2006) 399-406
32. Ikezawa Y. Cyclophosphamide decreases the number, percentage and the function of CD25+ CD4+ regulatory T cells, which suppress induction of contact hypersensitivity. J. Dermatol. Sci. 39 (2005) 105-112
33. Kudlacz E., et al. The novel JAK-3 inhibitor CP-690550 is a potent immunosuppressive agent in various murine models. Am. J. Transplant. 4 (2004) 51-57
34. Koo G.C., et al. Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol. 197 (1999) 99-107
35. Vana G., et al. Morphologic and immunohistochemical features of experimentally induced allergic contact dermatitis in Göttingen minipigs. Vet. Pathol. 37 (2000) 565-580
36. Imamura T. Role of macrophage tissue factor in the development of the delayed hypersensitivity reaction in monkey skin. Cell Immunol 152 (1993) 614-622
37. Chege G.K., et al. The immune response of the Chacma baboon to Bacille Calmette Guerin: development of a primate model for BCG-based vaccine research. Vaccine 23 (2005) 5783-5791
38. Kesavan A.K., et al. Effects of dexamethasone and transient malnutrition on rabbits infected with aerosolized Mycobacterium tuberculosis CDC1551. Infect. Immun. 73 (2005) 7056-7060
39. England R.W., et al. High-dose inhaled fluticasone and delayed hypersensitivity skin testing. Chest 123 (2003) 1014-1017
40. Persohn E., et al. Cell proliferation measurement in cecum and colon of rats using scanned images and fully automated image analysis: validation of method. Exp. Toxicol. Pathol. 58 (2007) 411-418